

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Honliv Healthcare Management Group Company Limited

宏力醫療管理集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9906)

INSIDE INFORMATION

POSSIBLE DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS POSTPONEMENT OF BOARD MEETING AND POSSIBLE SUSPENSION OF TRADING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) Honliv Healthcare Management Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

POSSIBLE DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) that it is expected that there may be a delay in publication of the Company’s audited annual results for the year ended 31 December 2025 (the “**2025 Audited Annual Results**”) as the Company requires additional time to preparation of the financial statement for the period, the Company is in discussion with its auditor regarding the status of the 2025 Audited Annual Results.

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the 2025 Audited Annual Results not later than three months after the end of the financial year (i.e. on or before 31 March 2026). It is further stated in Rule 13.49(2) of the Listing Rules, the preliminary announcement in relation to the 2025 Audited Annual Results shall be based on the Company's financial statements for the year ended 31 December 2024, which shall have been agreed with the Company's auditor. In light of the aforementioned circumstances, it is expected that the Company may be unable to publish the 2025 Audited Annual Results on or before 31 March 2026. The 2025 Audited Annual Results will be published promptly upon completion of the audit process.

Pursuant to Rule 13.49(3) of the Listing Rules, if the Company is unable to publish the 2025 Audited Annual Results within the prescribed timeframe, it must announce its results prepared based on the financial results which have yet to be agreed upon with its auditor (so far as such information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended 31 December 2025 at this stage as they may not accurately reflect the financial performance and/or position of the Group and the publication of the unaudited management accounts could cause confusion and may be misleading to the Shareholders and potential investors of the Company.

POSTPONEMENT OF THE DATE OF BOARD MEETING

As a result of the aforementioned possible delay in publication of the 2025 Audited Annual Results, the Company will also postpone the meeting of the Board for the purpose of considering and approving the 2025 Audited Annual Results and its publications, and considering the declaration of a final dividend, if any.

The Company will make further announcement(s) in accordance with Rule 13.43 of the Listing Rules as and when appropriate.

POSSIBLE SUSPENSION OF TRADING

Pursuant to Rule 13.50 of the Listing Rules, the Stock Exchange will normally require suspension of trading in an issuer's securities if an issuer fails to publish periodic financial information in accordance with the Listing Rules. The suspension will normally remain in force until the issuer publishes an announcement containing the requisite financial information.

In the event that the Company is unable to publish the 2025 Audited Annual Results on or before 31 March 2026, trading in the shares of the Company on the Stock Exchange is expected to be suspended with effect from 9:00 a.m. on Wednesday, 1 April 2026 until the publication of the 2025 Audited Annual Results by the Company.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Honliv Healthcare Management Group Company Limited
Qin Yan
Chairman

Hong Kong, 19 March 2026

As at the date of this announcement, the Board comprises Mr. Qin Yan, Mr. Wang Zhongtao and Ms. Li Yanhong as the executive directors; Mr. Qin Hongchao as the non-executive director; and Mr. Zhao Chun, Mr. Sun Jigang and Mr. Jiang Tianfan as the independent non-executive directors.